Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Vaccines
Researchers from National Institutes of Health report on findings in cancer vaccines
August 27th, 2008
Researchers detail in 'Analysis of overall survival in patients with nonmetastatic castration-resistant prostate cancer treated with vaccine, nilutamide, and combination therapy,' new data in cancer. "We reported previously the first randomized study of any kind in patients with nonmetastatic, castrate-resistant prostate cancer. The study employed vaccine, the hormone nilutamide, and the combined therapy (crossover for each arm) with an endpoint of time to progression," scientists in the United States report. "We now report survival analyses at 6.5 years from the initiation of therapy with a median potential follow-up of 4.4 years. Forty-two patients were randomized to...
Source: Vaccine Weekly (2008-08-27)
|
